Acute and Late Toxicity after Moderate Hypofractionation with Simultaneous Integrated Boost (SIB) Radiation Therapy for Prostate Cancer. A Single Institution, Prospective Study

Asbtract To evaluate the acute and late toxicity using moderately hypofractionated, intensity-modulated radiotherapy (IMRT) with a simultaneous integrated boost (SIB) to prostate for patients with intermediate and high risk prostate cancer. From 2015 to 2017, 162 patients were treated with IMRT with...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Pathology oncology research 2020-04, Vol.26 (2), p.905-912
Hauptverfasser: Jorgo, Kliton, Polgar, Csaba, Major, Tibor, Stelczer, Gabor, Herein, Andras, Pocza, Tamas, Gesztesi, Laszlo, Agoston, Peter
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 912
container_issue 2
container_start_page 905
container_title Pathology oncology research
container_volume 26
creator Jorgo, Kliton
Polgar, Csaba
Major, Tibor
Stelczer, Gabor
Herein, Andras
Pocza, Tamas
Gesztesi, Laszlo
Agoston, Peter
description Asbtract To evaluate the acute and late toxicity using moderately hypofractionated, intensity-modulated radiotherapy (IMRT) with a simultaneous integrated boost (SIB) to prostate for patients with intermediate and high risk prostate cancer. From 2015 to 2017, 162 patients were treated with IMRT with SIB to the prostate. IMRT plans were designed to deliver 50.4Gy in 28 fractions (1.8 Gy/fraction) to the pelvic lymph nodes (whole pelvis radiotherapy, WPRT) while simultaneously delivering 57.4 Gy in 28 fractions (2.05 Gy/fraction) to the seminal vesicles and 70 Gy in 28 fractions (2.5 Gy/fraction) to the prostate for high risk patients. For intermediate risk patients the same technique was applied, without WPRT. Acute and cumulative late genitourinary (GU) and gastrointestinal (GI) toxicities were scored according to the Radiation Therapy Oncology Group (RTOG) scoring system. Of the 162 patients enrolled, 156 (96%) completed the treatment as planned. The median follow-up time was 30 months. Seventy-eight patients (48.2%) were treated with WPRT. The rate of acute grade ≥ 2 GI and GU toxicities in all patients were 22% and 58%, respectively. The rate of cumulative late grade ≥ 2 GI and GU toxicities were 11% and 17%, respectively. Acute grade 3 GI and GU toxicities occurred in 1% and 1%. Late grade 3 GI and GU side effects occurred in 5% and 4%, respectively. None of the patients developed grade ≥ 4 toxicity. IMRT with SIB technique using moderate hypofractionation to the prostate is feasible treatment option for intermediate and high risk patients, associated with low rate of severe GU and GI toxicities.
doi_str_mv 10.1007/s12253-019-00623-2
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7242260</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2405674755</sourcerecordid><originalsourceid>FETCH-LOGICAL-c502t-6e0db1d3726ba9cb1e456be53ec7fe08af14ae67150c37f23a99071fc27a53343</originalsourceid><addsrcrecordid>eNp9ks9u1DAQxiMEoqXwAhyQJS4gkeL_Ti5I2xXQlRaB2OVsOc5k19VuHBynkLfiEXGaUuDSiz3y_L5vxvZk2XOCzwnG6m1PKBUsx6TMMZaU5fRBdkoEozktsHqYYppSvBTyJHvS91c4iWQpH2cnDBdFIbk8zX4t7BABmbZGa5OCrf_prIsjMk2EgD75GsJ0fjl2vgnGRudbMy3oh4t7tHHH4RBNC37o0aqNsJvoGl1430f0arO6eI2-mtrNku0-mXUjanxAX0IiJuelaS2Ec7RIZu3uAMmmjy4Ok-LNDdZBKnsNaBOHenyaPWrMoYdnt_tZ9u3D--3yMl9__rhaLta5FZjGXAKuK1IzRWVlSlsR4EJWIBhY1QAuTEO4AamIwJaphjJTlliRxlJlBGOcnWXvZt9uqI5QW2hjMAfdBXc0YdTeOP1_pnV7vfPXWlFOqcTJ4OWtQfDfB-ijvvJDaFPPmnIspOJKiHspUrKi5ByXiaIzZdNz9AGauz4I1tMs6HkWdJoFfTMLmibRi39vcCf58_kJYDPQp1S7g_C39j22vwHrYMKm</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2193894409</pqid></control><display><type>article</type><title>Acute and Late Toxicity after Moderate Hypofractionation with Simultaneous Integrated Boost (SIB) Radiation Therapy for Prostate Cancer. A Single Institution, Prospective Study</title><source>MEDLINE</source><source>SpringerNature Journals</source><creator>Jorgo, Kliton ; Polgar, Csaba ; Major, Tibor ; Stelczer, Gabor ; Herein, Andras ; Pocza, Tamas ; Gesztesi, Laszlo ; Agoston, Peter</creator><creatorcontrib>Jorgo, Kliton ; Polgar, Csaba ; Major, Tibor ; Stelczer, Gabor ; Herein, Andras ; Pocza, Tamas ; Gesztesi, Laszlo ; Agoston, Peter</creatorcontrib><description>Asbtract To evaluate the acute and late toxicity using moderately hypofractionated, intensity-modulated radiotherapy (IMRT) with a simultaneous integrated boost (SIB) to prostate for patients with intermediate and high risk prostate cancer. From 2015 to 2017, 162 patients were treated with IMRT with SIB to the prostate. IMRT plans were designed to deliver 50.4Gy in 28 fractions (1.8 Gy/fraction) to the pelvic lymph nodes (whole pelvis radiotherapy, WPRT) while simultaneously delivering 57.4 Gy in 28 fractions (2.05 Gy/fraction) to the seminal vesicles and 70 Gy in 28 fractions (2.5 Gy/fraction) to the prostate for high risk patients. For intermediate risk patients the same technique was applied, without WPRT. Acute and cumulative late genitourinary (GU) and gastrointestinal (GI) toxicities were scored according to the Radiation Therapy Oncology Group (RTOG) scoring system. Of the 162 patients enrolled, 156 (96%) completed the treatment as planned. The median follow-up time was 30 months. Seventy-eight patients (48.2%) were treated with WPRT. The rate of acute grade ≥ 2 GI and GU toxicities in all patients were 22% and 58%, respectively. The rate of cumulative late grade ≥ 2 GI and GU toxicities were 11% and 17%, respectively. Acute grade 3 GI and GU toxicities occurred in 1% and 1%. Late grade 3 GI and GU side effects occurred in 5% and 4%, respectively. None of the patients developed grade ≥ 4 toxicity. IMRT with SIB technique using moderate hypofractionation to the prostate is feasible treatment option for intermediate and high risk patients, associated with low rate of severe GU and GI toxicities.</description><identifier>ISSN: 1219-4956</identifier><identifier>EISSN: 1532-2807</identifier><identifier>DOI: 10.1007/s12253-019-00623-2</identifier><identifier>PMID: 30888646</identifier><language>eng</language><publisher>Dordrecht: Springer Netherlands</publisher><subject>Aged ; Aged, 80 and over ; Biomedical and Life Sciences ; Biomedicine ; Cancer Research ; Health risks ; Humans ; Immunology ; Lymph nodes ; Male ; Middle Aged ; Oncology ; Original ; Original Article ; Pathology ; Patients ; Pelvis ; Prostate cancer ; Prostatic Neoplasms - radiotherapy ; Radiation ; Radiation Dose Hypofractionation ; Radiation Injuries - epidemiology ; Radiation therapy ; Radiotherapy, Intensity-Modulated - adverse effects ; Radiotherapy, Intensity-Modulated - methods ; Risk groups ; Seminal vesicle ; Toxicity</subject><ispartof>Pathology oncology research, 2020-04, Vol.26 (2), p.905-912</ispartof><rights>The Author(s) 2019</rights><rights>Pathology &amp; Oncology Research is a copyright of Springer, (2019). All Rights Reserved. © 2019. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>The Author(s) 2019. This work is published under https://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c502t-6e0db1d3726ba9cb1e456be53ec7fe08af14ae67150c37f23a99071fc27a53343</citedby><cites>FETCH-LOGICAL-c502t-6e0db1d3726ba9cb1e456be53ec7fe08af14ae67150c37f23a99071fc27a53343</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s12253-019-00623-2$$EPDF$$P50$$Gspringer$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s12253-019-00623-2$$EHTML$$P50$$Gspringer$$Hfree_for_read</linktohtml><link.rule.ids>230,314,780,784,885,27924,27925,41488,42557,51319</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30888646$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Jorgo, Kliton</creatorcontrib><creatorcontrib>Polgar, Csaba</creatorcontrib><creatorcontrib>Major, Tibor</creatorcontrib><creatorcontrib>Stelczer, Gabor</creatorcontrib><creatorcontrib>Herein, Andras</creatorcontrib><creatorcontrib>Pocza, Tamas</creatorcontrib><creatorcontrib>Gesztesi, Laszlo</creatorcontrib><creatorcontrib>Agoston, Peter</creatorcontrib><title>Acute and Late Toxicity after Moderate Hypofractionation with Simultaneous Integrated Boost (SIB) Radiation Therapy for Prostate Cancer. A Single Institution, Prospective Study</title><title>Pathology oncology research</title><addtitle>Pathol. Oncol. Res</addtitle><addtitle>Pathol Oncol Res</addtitle><description>Asbtract To evaluate the acute and late toxicity using moderately hypofractionated, intensity-modulated radiotherapy (IMRT) with a simultaneous integrated boost (SIB) to prostate for patients with intermediate and high risk prostate cancer. From 2015 to 2017, 162 patients were treated with IMRT with SIB to the prostate. IMRT plans were designed to deliver 50.4Gy in 28 fractions (1.8 Gy/fraction) to the pelvic lymph nodes (whole pelvis radiotherapy, WPRT) while simultaneously delivering 57.4 Gy in 28 fractions (2.05 Gy/fraction) to the seminal vesicles and 70 Gy in 28 fractions (2.5 Gy/fraction) to the prostate for high risk patients. For intermediate risk patients the same technique was applied, without WPRT. Acute and cumulative late genitourinary (GU) and gastrointestinal (GI) toxicities were scored according to the Radiation Therapy Oncology Group (RTOG) scoring system. Of the 162 patients enrolled, 156 (96%) completed the treatment as planned. The median follow-up time was 30 months. Seventy-eight patients (48.2%) were treated with WPRT. The rate of acute grade ≥ 2 GI and GU toxicities in all patients were 22% and 58%, respectively. The rate of cumulative late grade ≥ 2 GI and GU toxicities were 11% and 17%, respectively. Acute grade 3 GI and GU toxicities occurred in 1% and 1%. Late grade 3 GI and GU side effects occurred in 5% and 4%, respectively. None of the patients developed grade ≥ 4 toxicity. IMRT with SIB technique using moderate hypofractionation to the prostate is feasible treatment option for intermediate and high risk patients, associated with low rate of severe GU and GI toxicities.</description><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>Cancer Research</subject><subject>Health risks</subject><subject>Humans</subject><subject>Immunology</subject><subject>Lymph nodes</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Oncology</subject><subject>Original</subject><subject>Original Article</subject><subject>Pathology</subject><subject>Patients</subject><subject>Pelvis</subject><subject>Prostate cancer</subject><subject>Prostatic Neoplasms - radiotherapy</subject><subject>Radiation</subject><subject>Radiation Dose Hypofractionation</subject><subject>Radiation Injuries - epidemiology</subject><subject>Radiation therapy</subject><subject>Radiotherapy, Intensity-Modulated - adverse effects</subject><subject>Radiotherapy, Intensity-Modulated - methods</subject><subject>Risk groups</subject><subject>Seminal vesicle</subject><subject>Toxicity</subject><issn>1219-4956</issn><issn>1532-2807</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>C6C</sourceid><sourceid>EIF</sourceid><recordid>eNp9ks9u1DAQxiMEoqXwAhyQJS4gkeL_Ti5I2xXQlRaB2OVsOc5k19VuHBynkLfiEXGaUuDSiz3y_L5vxvZk2XOCzwnG6m1PKBUsx6TMMZaU5fRBdkoEozktsHqYYppSvBTyJHvS91c4iWQpH2cnDBdFIbk8zX4t7BABmbZGa5OCrf_prIsjMk2EgD75GsJ0fjl2vgnGRudbMy3oh4t7tHHH4RBNC37o0aqNsJvoGl1430f0arO6eI2-mtrNku0-mXUjanxAX0IiJuelaS2Ec7RIZu3uAMmmjy4Ok-LNDdZBKnsNaBOHenyaPWrMoYdnt_tZ9u3D--3yMl9__rhaLta5FZjGXAKuK1IzRWVlSlsR4EJWIBhY1QAuTEO4AamIwJaphjJTlliRxlJlBGOcnWXvZt9uqI5QW2hjMAfdBXc0YdTeOP1_pnV7vfPXWlFOqcTJ4OWtQfDfB-ijvvJDaFPPmnIspOJKiHspUrKi5ByXiaIzZdNz9AGauz4I1tMs6HkWdJoFfTMLmibRi39vcCf58_kJYDPQp1S7g_C39j22vwHrYMKm</recordid><startdate>20200401</startdate><enddate>20200401</enddate><creator>Jorgo, Kliton</creator><creator>Polgar, Csaba</creator><creator>Major, Tibor</creator><creator>Stelczer, Gabor</creator><creator>Herein, Andras</creator><creator>Pocza, Tamas</creator><creator>Gesztesi, Laszlo</creator><creator>Agoston, Peter</creator><general>Springer Netherlands</general><general>Springer Nature B.V</general><scope>C6C</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7TM</scope><scope>7TO</scope><scope>7U9</scope><scope>H94</scope><scope>K9.</scope><scope>M7N</scope><scope>NAPCQ</scope><scope>5PM</scope></search><sort><creationdate>20200401</creationdate><title>Acute and Late Toxicity after Moderate Hypofractionation with Simultaneous Integrated Boost (SIB) Radiation Therapy for Prostate Cancer. A Single Institution, Prospective Study</title><author>Jorgo, Kliton ; Polgar, Csaba ; Major, Tibor ; Stelczer, Gabor ; Herein, Andras ; Pocza, Tamas ; Gesztesi, Laszlo ; Agoston, Peter</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c502t-6e0db1d3726ba9cb1e456be53ec7fe08af14ae67150c37f23a99071fc27a53343</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>Cancer Research</topic><topic>Health risks</topic><topic>Humans</topic><topic>Immunology</topic><topic>Lymph nodes</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Oncology</topic><topic>Original</topic><topic>Original Article</topic><topic>Pathology</topic><topic>Patients</topic><topic>Pelvis</topic><topic>Prostate cancer</topic><topic>Prostatic Neoplasms - radiotherapy</topic><topic>Radiation</topic><topic>Radiation Dose Hypofractionation</topic><topic>Radiation Injuries - epidemiology</topic><topic>Radiation therapy</topic><topic>Radiotherapy, Intensity-Modulated - adverse effects</topic><topic>Radiotherapy, Intensity-Modulated - methods</topic><topic>Risk groups</topic><topic>Seminal vesicle</topic><topic>Toxicity</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Jorgo, Kliton</creatorcontrib><creatorcontrib>Polgar, Csaba</creatorcontrib><creatorcontrib>Major, Tibor</creatorcontrib><creatorcontrib>Stelczer, Gabor</creatorcontrib><creatorcontrib>Herein, Andras</creatorcontrib><creatorcontrib>Pocza, Tamas</creatorcontrib><creatorcontrib>Gesztesi, Laszlo</creatorcontrib><creatorcontrib>Agoston, Peter</creatorcontrib><collection>Springer Nature OA Free Journals</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Pathology oncology research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Jorgo, Kliton</au><au>Polgar, Csaba</au><au>Major, Tibor</au><au>Stelczer, Gabor</au><au>Herein, Andras</au><au>Pocza, Tamas</au><au>Gesztesi, Laszlo</au><au>Agoston, Peter</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Acute and Late Toxicity after Moderate Hypofractionation with Simultaneous Integrated Boost (SIB) Radiation Therapy for Prostate Cancer. A Single Institution, Prospective Study</atitle><jtitle>Pathology oncology research</jtitle><stitle>Pathol. Oncol. Res</stitle><addtitle>Pathol Oncol Res</addtitle><date>2020-04-01</date><risdate>2020</risdate><volume>26</volume><issue>2</issue><spage>905</spage><epage>912</epage><pages>905-912</pages><issn>1219-4956</issn><eissn>1532-2807</eissn><abstract>Asbtract To evaluate the acute and late toxicity using moderately hypofractionated, intensity-modulated radiotherapy (IMRT) with a simultaneous integrated boost (SIB) to prostate for patients with intermediate and high risk prostate cancer. From 2015 to 2017, 162 patients were treated with IMRT with SIB to the prostate. IMRT plans were designed to deliver 50.4Gy in 28 fractions (1.8 Gy/fraction) to the pelvic lymph nodes (whole pelvis radiotherapy, WPRT) while simultaneously delivering 57.4 Gy in 28 fractions (2.05 Gy/fraction) to the seminal vesicles and 70 Gy in 28 fractions (2.5 Gy/fraction) to the prostate for high risk patients. For intermediate risk patients the same technique was applied, without WPRT. Acute and cumulative late genitourinary (GU) and gastrointestinal (GI) toxicities were scored according to the Radiation Therapy Oncology Group (RTOG) scoring system. Of the 162 patients enrolled, 156 (96%) completed the treatment as planned. The median follow-up time was 30 months. Seventy-eight patients (48.2%) were treated with WPRT. The rate of acute grade ≥ 2 GI and GU toxicities in all patients were 22% and 58%, respectively. The rate of cumulative late grade ≥ 2 GI and GU toxicities were 11% and 17%, respectively. Acute grade 3 GI and GU toxicities occurred in 1% and 1%. Late grade 3 GI and GU side effects occurred in 5% and 4%, respectively. None of the patients developed grade ≥ 4 toxicity. IMRT with SIB technique using moderate hypofractionation to the prostate is feasible treatment option for intermediate and high risk patients, associated with low rate of severe GU and GI toxicities.</abstract><cop>Dordrecht</cop><pub>Springer Netherlands</pub><pmid>30888646</pmid><doi>10.1007/s12253-019-00623-2</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1219-4956
ispartof Pathology oncology research, 2020-04, Vol.26 (2), p.905-912
issn 1219-4956
1532-2807
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7242260
source MEDLINE; SpringerNature Journals
subjects Aged
Aged, 80 and over
Biomedical and Life Sciences
Biomedicine
Cancer Research
Health risks
Humans
Immunology
Lymph nodes
Male
Middle Aged
Oncology
Original
Original Article
Pathology
Patients
Pelvis
Prostate cancer
Prostatic Neoplasms - radiotherapy
Radiation
Radiation Dose Hypofractionation
Radiation Injuries - epidemiology
Radiation therapy
Radiotherapy, Intensity-Modulated - adverse effects
Radiotherapy, Intensity-Modulated - methods
Risk groups
Seminal vesicle
Toxicity
title Acute and Late Toxicity after Moderate Hypofractionation with Simultaneous Integrated Boost (SIB) Radiation Therapy for Prostate Cancer. A Single Institution, Prospective Study
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T15%3A40%3A49IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Acute%20and%20Late%20Toxicity%20after%20Moderate%20Hypofractionation%20with%20Simultaneous%20Integrated%20Boost%20(SIB)%20Radiation%20Therapy%20for%20Prostate%20Cancer.%20A%20Single%20Institution,%20Prospective%20Study&rft.jtitle=Pathology%20oncology%20research&rft.au=Jorgo,%20Kliton&rft.date=2020-04-01&rft.volume=26&rft.issue=2&rft.spage=905&rft.epage=912&rft.pages=905-912&rft.issn=1219-4956&rft.eissn=1532-2807&rft_id=info:doi/10.1007/s12253-019-00623-2&rft_dat=%3Cproquest_pubme%3E2405674755%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2193894409&rft_id=info:pmid/30888646&rfr_iscdi=true